Company intelligence / Profile preview
Allygen Biologics
Shanghai, Shanghai, Chinaallogenbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ALG01, a next-generation anti-PD-L1×TROP-2 bispecific antibody-drug conjugate (BiADC) with STAR technology, demonstrated excellent anti-tumor efficacy and safety in preclinical studies. In toxicology studies, ALG01 was well tolerated in cynomolgus monkeys, with the highest non-severely toxic dose (HNSTD) observed at ≥45 mg/kg for DAR6 or ≥65 mg/kg for DAR4. An IND application is planned for submission in 2025.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Bispecific antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Allygen Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allygen Biologics.